Surmodics, Inc. (SRDX) demonstrated strong performance in the last reported quarter. Its loss per share was 51.9% narrower than the market estimate, and sales beat the same by 8.3%. The strong performance was driven by the company’s solid prospects in the thrombectomy business.Meanwhile, SRDX is likely to be acquired by GTCR, a renowned private equity company, for an estimated $627 million in total equity valuation. Although the deal is expected to be closed by March-end and take SRDX private, adding it to ...